Condition: Wet Age-related Macular Degeneration · Sponsor: Parc de Salut Mar
This is a phase III, multicenter, randomized double-blinded clinical trial with two parallel groups (ranibizumab and bevacizumab) and an observational follow-up of patients who meet elegibility criteria and decline participation due to treatment randomization. It will be performed involving 630 eyes from patients with wet age-related macular degeneration (wAMD) diagnosis without another eye disease. This clinical trial compares the treatment response for 3 years, considering genetic variants already studied between the eyes treated with one of the first options of anti-VEGF used in patients with wAMD, (ranibizumab) and the most cost-effective anti-VEGF (bevacizumab; off-label use)
This description comes directly from the study's public registry record.
Ana Aldea · +3431604900 · aaldea@imim.es
Melina Rojas · mrojas@researchmar.net
Always discuss trial participation with your own doctor first.
| Hospital Universitario de Canarias | San Cristóbal de La Laguna, Santa Cruz De Tenerife, Spain | Recruiting |
| Hospital de la Santa Creu i Sant Pau | Barcelona, Spain | Recruiting |
| Hospital la Esperanza | Barcelona, Spain | Recruiting |
| Unidad Central de Investigación Clínica y Ensayos Clínicos (UCICEC La Paz) | Madrid, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06952452